Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

Gennova has been working on self-amplifying mRNA vaccine. mRNA vaccines use body’s machinery to make antigenic protein rather ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Given the stock’s generous 7% yield, maybe junk bond investors should take a look.The venerable drug company, which also ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...